- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
HBA 2020 Woman of the Year Announced
The Healthcare Businesswomen’s Association (HBA) last night announced the 2020 Woman of the Year during a reception at the J.P. Morgan Healthcare Conference.
Dr. Sandra Horning, former chief medical officer and head of global product development, Genentech and Roche, will be recognized at the HBA’s 31st annual Woman of the Year event on 29 April in New York City.
The HBA Woman of the Year award honors a female senior executive whose accomplishments have resulted in significant contributions to the healthcare industry.
During her tenure at Genentech and Roche, Dr. Horning helped to bring 15 new medicines to patients in neuroscience, ophthalmology, immunology, infectious disease and hematology/oncology. Driving for early access to life-saving medicines, she collaborated with the FDA and others in breakthrough therapy designation and early endpoints for regulatory approval. As a distinguished clinical investigator, she has been recognized as a global leader in the field of hematology/oncology and a respected clinician and scientist at the cutting edge of cancer research.
Beyond her contributions to medicine, Dr. Horning has been a passionate advocate for women in leadership both in the academy and in the office. During her tenure, gender parity increased across product development at Genentech and Roche at the senior leadership level. Currently, all five global product development sites at Genentech and Roche are led by women.
Look out for Pharm Exec’s cover profile of Dr. Sandra Horning in the April 2020 issue.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
